EP 0628043 A1 19941214 - 2,6-METHANO-2H-QUINOLIZIN DERIVATIVE AS 5-HT3-RECEPTOR ANTAGONIST.
Title (en)
2,6-METHANO-2H-QUINOLIZIN DERIVATIVE AS 5-HT3-RECEPTOR ANTAGONIST.
Title (de)
216-METHANO-2H-QUINOLIZINE DERIVATE ALS 5-HT3 REZEPTOR ANTAGONIST.
Title (fr)
DERIVE DE 2,6-METHANO-2H-QUINOLIZINE UTILISE COMME ANTAGONISTE DE RECEPTEUR DE 5-HT 3?.
Publication
Application
Priority
- EP 93904797 A 19930203
- EP 92400474 A 19920224
- US 9300880 W 19930203
Abstract (en)
[origin: WO9317019A1] This invention relates to 5-chloro-2, 3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acid-octahydro-3-hydroxy-2,6-methano-2H-quinolizin-8-yl ester (I), a novel 5-HT3-receptor antagonist, its method of preparation, and to its end-use application in the treatment of radio- and chemo-therapeutically-induced nausea and vomiting, in the treatment of pain associated with migraine, in the treatment of cognitive disorders, in treating hallucinatory endogenous psychoses of the type manifested in patients suffering from schizophrenia and mania, for irritable bowel syndrome, and to combat drug abuse.
Abstract (fr)
Cette invention se rapporte à l'ester de 5-chloro-2,3-dihydro-2, 2-diméthylbenzofuran-7-acide carboxylique-octahydro-3-hydroxy-2,6-méthano-2H-qquinolizin-8-yle (I). Un nouvel antagoniste de récepteur de 5-HT3, à un procédé destiné à sa préparation et à l'utilisation finale à laquelle il est destiné notamment pour le traitement de vomissements et de nausées induites par radio ou chimiothérapie, le traitement de douleurs associées à la migraine et le traitement de troubles cognitifs, ainsi que le traitement de psychoses endogènes hallucinatoires du type présenté par des patients souffrant de schizophrénie et de manie, le traitement du côlon irritable et pour lutter contre la toxicomanie.
IPC 1-7
IPC 8 full level
A61K 31/435 (2006.01); A61P 1/08 (2006.01); A61P 25/04 (2006.01); A61P 25/18 (2006.01); A61P 25/24 (2006.01); A61P 25/26 (2006.01); C07D 471/18 (2006.01)
CPC (source: EP KR)
A61K 31/435 (2013.01 - KR); A61P 1/08 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/04 (2017.12 - EP); A61P 25/18 (2017.12 - EP); A61P 25/24 (2017.12 - EP); A61P 25/26 (2017.12 - EP); C07D 471/18 (2013.01 - EP KR)
Citation (search report)
See references of WO 9317019A1
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9317019 A1 19930902; AU 3603493 A 19930913; AU 675060 B2 19970123; CA 2130563 A1 19930902; CA 2130563 C 19971111; EP 0628043 A1 19941214; FI 105917 B 20001031; FI 943872 A0 19940823; FI 943872 A 19940823; HU 216831 B 19990928; HU 9402436 D0 19941028; HU T68249 A 19950628; IL 104821 A0 19930610; IL 104821 A 19970110; JP H07504192 A 19950511; KR 100287933 B1 20010502; KR 950700297 A 19950116; MX 9300948 A 19930801; NO 943101 D0 19940823; NO 943101 L 19940823; NZ 249346 A 19951026; TW 226374 B 19940711; ZA 931146 B 19930914
DOCDB simple family (application)
US 9300880 W 19930203; AU 3603493 A 19930203; CA 2130563 A 19930203; EP 93904797 A 19930203; FI 943872 A 19940823; HU 9402436 A 19930203; IL 10482193 A 19930222; JP 51486893 A 19930203; KR 19940702945 A 19940824; MX 9300948 A 19930222; NO 943101 A 19940823; NZ 24934693 A 19930203; TW 82101189 A 19930219; ZA 931146 A 19930218